MXPA04012604A - áCIDO 3-MERCAPTOPENTANOICO 2,5 DISUSTITUIDO. - Google Patents
áCIDO 3-MERCAPTOPENTANOICO 2,5 DISUSTITUIDO.Info
- Publication number
- MXPA04012604A MXPA04012604A MXPA04012604A MXPA04012604A MXPA04012604A MX PA04012604 A MXPA04012604 A MX PA04012604A MX PA04012604 A MXPA04012604 A MX PA04012604A MX PA04012604 A MXPA04012604 A MX PA04012604A MX PA04012604 A MXPA04012604 A MX PA04012604A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- solvates
- pharmaceutically acceptable
- disubstituted
- carboxypeptidase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se relaciona con compuestos de formula (I), y sales o solvatos farmaceuticamente aceptables de los mismos, o solvatos de esas sales, compuestos los cuales inhiben la carboxipeptidasa U y de este modo puede ser usados en la prevencion o tratamiento de enfermedades donde la inhibicion de la carboxipeptidasa U es benefica. En aspectos adicionales, la invencion se relaciona con compuestos de la invencion para usarse en terapia; con procesos para la preparacion de esos compuestos novedosos; con composiciones farmaceuticas que contiene al menos un compuesto de la invencion, o una sal o solvato farmaceuticamente aceptable del mismo como ingrediente activo; y con el uso de los compuestos activos en la elaboracion de medicamentos para el uso medico indicado anteriormente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201837A SE0201837D0 (sv) | 2002-06-14 | 2002-06-14 | Chemical compounds |
| PCT/SE2003/000970 WO2003106420A1 (en) | 2002-06-14 | 2003-06-10 | 2,5-disubstituted 3-mercaptopentanoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04012604A true MXPA04012604A (es) | 2005-03-23 |
Family
ID=20288202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04012604A MXPA04012604A (es) | 2002-06-14 | 2003-06-10 | áCIDO 3-MERCAPTOPENTANOICO 2,5 DISUSTITUIDO. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7572817B2 (es) |
| EP (1) | EP1532111B1 (es) |
| JP (1) | JP2005533064A (es) |
| KR (1) | KR20050010051A (es) |
| CN (1) | CN100415719C (es) |
| AR (1) | AR040240A1 (es) |
| AT (1) | ATE369342T1 (es) |
| AU (1) | AU2003241260B2 (es) |
| BR (1) | BR0311384A (es) |
| CA (1) | CA2488606A1 (es) |
| CY (1) | CY1107753T1 (es) |
| DE (1) | DE60315471T2 (es) |
| DK (1) | DK1532111T3 (es) |
| ES (1) | ES2289297T3 (es) |
| HK (1) | HK1077296A1 (es) |
| IS (1) | IS7609A (es) |
| MX (1) | MXPA04012604A (es) |
| MY (1) | MY160429A (es) |
| NO (1) | NO20045051L (es) |
| NZ (1) | NZ536814A (es) |
| PL (1) | PL373883A1 (es) |
| PT (1) | PT1532111E (es) |
| RU (1) | RU2365583C2 (es) |
| SA (1) | SA03240142B1 (es) |
| SE (1) | SE0201837D0 (es) |
| TW (1) | TW200401766A (es) |
| UA (1) | UA78042C2 (es) |
| WO (1) | WO2003106420A1 (es) |
| ZA (1) | ZA200409955B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| GB0403864D0 (en) | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
| CA2600869A1 (en) * | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
| WO2010050525A1 (ja) | 2008-10-29 | 2010-05-06 | 大正製薬株式会社 | ＴＡＦＩａ阻害活性を有する化合物 |
| US20140303098A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN105377266A (zh) | 2013-04-18 | 2016-03-02 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
| KR20160018557A (ko) | 2013-06-10 | 2016-02-17 | 사노피 | TAFIa의 저해제로서의 마크로사이클릭 우레아 유도체, 이의 제법 및 의약품으로서의 이의 용도 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4687500A (en) * | 1999-04-29 | 2000-11-17 | Allergan Sales, Inc. | Thromboxane ligands without blood clotting side effects |
| SE9901573D0 (sv) | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
-
2002
- 2002-06-14 SE SE0201837A patent/SE0201837D0/xx unknown
-
2003
- 2003-06-02 AR ARP030101959A patent/AR040240A1/es unknown
- 2003-06-08 SA SA03240142A patent/SA03240142B1/ar unknown
- 2003-06-10 CA CA002488606A patent/CA2488606A1/en not_active Abandoned
- 2003-06-10 RU RU2004134563/04A patent/RU2365583C2/ru not_active IP Right Cessation
- 2003-06-10 NZ NZ536814A patent/NZ536814A/en unknown
- 2003-06-10 WO PCT/SE2003/000970 patent/WO2003106420A1/en active IP Right Grant
- 2003-06-10 DE DE60315471T patent/DE60315471T2/de not_active Expired - Fee Related
- 2003-06-10 MX MXPA04012604A patent/MXPA04012604A/es active IP Right Grant
- 2003-06-10 PL PL03373883A patent/PL373883A1/xx not_active Application Discontinuation
- 2003-06-10 ES ES03730987T patent/ES2289297T3/es not_active Expired - Lifetime
- 2003-06-10 EP EP03730987A patent/EP1532111B1/en not_active Expired - Lifetime
- 2003-06-10 BR BR0311384-1A patent/BR0311384A/pt not_active IP Right Cessation
- 2003-06-10 AU AU2003241260A patent/AU2003241260B2/en not_active Ceased
- 2003-06-10 KR KR10-2004-7020285A patent/KR20050010051A/ko not_active Application Discontinuation
- 2003-06-10 JP JP2004513253A patent/JP2005533064A/ja not_active Withdrawn
- 2003-06-10 US US10/517,713 patent/US7572817B2/en not_active Expired - Fee Related
- 2003-06-10 PT PT03730987T patent/PT1532111E/pt unknown
- 2003-06-10 CN CNB038138409A patent/CN100415719C/zh not_active Expired - Fee Related
- 2003-06-10 DK DK03730987T patent/DK1532111T3/da active
- 2003-06-10 AT AT03730987T patent/ATE369342T1/de not_active IP Right Cessation
- 2003-06-12 TW TW092115988A patent/TW200401766A/zh unknown
- 2003-06-12 MY MYPI20032192A patent/MY160429A/en unknown
- 2003-10-06 UA UA20041109447A patent/UA78042C2/uk unknown
-
2004
- 2004-11-19 NO NO20045051A patent/NO20045051L/no not_active Application Discontinuation
- 2004-12-08 ZA ZA200409955A patent/ZA200409955B/en unknown
- 2004-12-22 IS IS7609A patent/IS7609A/is unknown
-
2005
- 2005-10-14 HK HK05109105A patent/HK1077296A1/xx not_active IP Right Cessation
-
2007
- 2007-10-08 CY CY20071101274T patent/CY1107753T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IS7609A (is) | 2004-12-22 |
| AR040240A1 (es) | 2005-03-23 |
| BR0311384A (pt) | 2005-03-15 |
| RU2004134563A (ru) | 2005-07-20 |
| AU2003241260B2 (en) | 2007-04-26 |
| NZ536814A (en) | 2006-11-30 |
| US20050176780A1 (en) | 2005-08-11 |
| US7572817B2 (en) | 2009-08-11 |
| MY160429A (en) | 2017-03-15 |
| EP1532111B1 (en) | 2007-08-08 |
| SA03240142B1 (ar) | 2007-07-31 |
| WO2003106420A1 (en) | 2003-12-24 |
| DE60315471D1 (de) | 2007-09-20 |
| DE60315471T2 (de) | 2008-04-24 |
| PL373883A1 (en) | 2005-09-19 |
| AU2003241260A1 (en) | 2003-12-31 |
| JP2005533064A (ja) | 2005-11-04 |
| CN1662504A (zh) | 2005-08-31 |
| TW200401766A (en) | 2004-02-01 |
| DK1532111T3 (da) | 2007-10-22 |
| RU2365583C2 (ru) | 2009-08-27 |
| EP1532111A1 (en) | 2005-05-25 |
| SE0201837D0 (sv) | 2002-06-14 |
| CA2488606A1 (en) | 2003-12-24 |
| UA78042C2 (en) | 2007-02-15 |
| KR20050010051A (ko) | 2005-01-26 |
| ATE369342T1 (de) | 2007-08-15 |
| ES2289297T3 (es) | 2008-02-01 |
| NO20045051L (no) | 2005-01-13 |
| PT1532111E (pt) | 2007-09-25 |
| CN100415719C (zh) | 2008-09-03 |
| ZA200409955B (en) | 2006-08-30 |
| CY1107753T1 (el) | 2013-04-18 |
| HK1077296A1 (en) | 2006-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE9901573D0 (sv) | New compounds | |
| MXPA05001581A (es) | Algunas imidazopiridinas novedosas y su uso. | |
| ZA200501098B (en) | Novel use of benzothiazole derivatives | |
| RU95102778A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен | |
| WO2004037807A3 (en) | Medicinal arylethanolamine compounds | |
| AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
| CY1107753T1 (el) | 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ | |
| MD523G2 (ro) | Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin | |
| DK0920865T3 (da) | Farmaceutiske sammensætninger indeholdende norastemizol | |
| HK1045464A1 (en) | Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease | |
| WO2002000166A3 (en) | New compounds useful as antibacterial agents | |
| HK1087039A1 (en) | Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass | |
| WO2000066550A8 (en) | New compounds | |
| WO2002064552A8 (en) | 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | |
| SE0103272D0 (sv) | Chemical compounds | |
| HUT48588A (en) | Process for production of derivatives of 4-/aroil-amin/-piperidin buthan amid and medical preparatives containg these substances | |
| CA2373962A1 (en) | Immediate release medicinal compositions for oral use | |
| MY133438A (en) | Morpholinobenzamide salts | |
| US4156003A (en) | Treatment of hypertension with combination of clofibrinic acid or clofibrate with cinnarizine | |
| EP1291349A4 (en) | MALTO-OLIGOSACCHARIDE DERIVATIVES AND USE THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |